New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
15:21 EDTBMRNBioMarin's Vimizim gets FDA approval to treat enzyme disorder
The U.S. Food and Drug Administration approved Vimizim, the first FDA-approved treatment for Mucopolysaccharidosis Type IVA. Vimizim is intended to replace the missing GALNS enzyme involved in an important metabolic pathway. Vimizim was granted priority review. An FDA priority review provides for an expedited review of drugs for serious diseases or conditions that may offer major advances in treatment. Vimizim is also the first drug to receive the Rare Pediatric Disease Priority Review Voucher, a provision that aims to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. Vimizim is marketed by BioMarin Pharmaceutical. Reference Link
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2015
07:59 EDTBMRNBioMarin gene therapy an overhang for Baxalta, says JPMorgan
Subscribe for More Information
July 20, 2015
14:32 EDTBMRNFDA panel likely to review Sarepta, BioMarin drugs in November, TheStreet says
Subscribe for More Information
11:03 EDTBMRNSarepta rises after Roth says added data can keep it ahead of BioMarin
Subscribe for More Information
08:47 EDTBMRNBioMarin reports Abrazo Phase 2 trial met threshold for tumor reduction
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use